Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Mar. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 2,598.3	$ 2,375.0
Inventory	2,273.9	2,460.5
Other current assets	757.3	752.5
Total current assets	7,626.0	7,456.8
Property, plant and equipment, net	3,132.4	3,181.3
Operating lease assets	346.4	356.4
Intangible assets, net	9,584.6	9,691.2
Goodwill	6,477.1	6,478.9
Deferred tax asset	307.5	324.2
Investments and other assets	559.1	560.5
Total assets	28,033.1	28,049.3
Current liabilities:
Current portion of notes payable	1,749.1	1,748.6
Taxes payable	626.1	548.3
Accounts payable	391.5	424.2
Accrued expense and other	2,530.7	2,807.7
Total current liabilities	5,297.4	5,528.8
Notes payable	4,548.7	4,547.2
Deferred tax liability	133.2	190.5
Long-term operating lease liabilities	323.4	334.5
Other long-term liabilities	751.7	732.3
Total liabilities	11,054.4	11,333.3
Commitments, contingencies and guarantees
Biogen Inc. shareholders’ equity:
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	629.9	569.4
Accumulated other comprehensive income (loss)	(174.5)	(136.2)
Retained earnings	19,500.3	19,259.8
Treasury stock, at cost	(2,977.1)	(2,977.1)
Total equity	16,978.7	16,716.0
Total liabilities and equity	28,033.1	28,049.3
Nonrelated Party
Current assets:
Accounts receivable, net of allowance for doubtful accounts of $1.4 and $2.2, respectively	1,602.9	1,404.8
Related Party
Current assets:
Accounts receivable, net of allowance for doubtful accounts of $1.4 and $2.2, respectively	$ 393.6	$ 464.0